Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,314
Out of 5,024 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $34.64 | +21.25% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $129.79 | +188.93% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $71.21 | +61.49% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $74.08 | +24.19% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $17.26 | -30.48% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $9.14 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $44.40 | +102.70% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $237.81 | +13.54% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $85.32 | -20.30% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $11.00 | +309.09% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $122.28 | +124.89% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $27.10 | +36.56% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $66.21 | -9.38% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $96.24 | -63.63% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $318.30 | -74.55% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $34.64
Upside: +21.25%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $129.79
Upside: +188.93%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $71.21
Upside: +61.49%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $74.08
Upside: +24.19%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $17.26
Upside: -30.48%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.14
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $44.40
Upside: +102.70%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $237.81
Upside: +13.54%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $85.32
Upside: -20.30%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $11.00
Upside: +309.09%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $122.28
Upside: +124.89%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $27.10
Upside: +36.56%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $66.21
Upside: -9.38%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $96.24
Upside: -63.63%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $318.30
Upside: -74.55%